Cerebral Cavernous Malformation
Cerebral cavernous malformations are collections of small blood vessels (capillaries) in the brain that are enlarged and irregular in structure. These capillaries have abnormally thin walls, and they lack other support tissues, such as elastic fibers, which normally make them stretchy. As a result, the blood vessels are prone to leakage, which can cause the health problems related to this condition. Cavernous malformations can occur anywhere in the body, but usually produce serious signs and symptoms only when they occur in the brain and spinal cord (which are described as cerebral).
Approximately 25 percent of individuals with cerebral cavernous malformations never experience any related health problems. Other people with this condition may experience serious signs and symptoms such as headaches, seizures, paralysis, hearing or vision loss, and bleeding in the brain (cerebral hemorrhage). Severe brain hemorrhages can result in death. The location and number of cerebral cavernous malformations determine the severity of this disorder. These malformations can change in size and number over time.
There are two forms of the condition: familial and sporadic. The familial form is passed from parent to child, and affected individuals typically have multiple cerebral cavernous malformations. The sporadic form occurs in people with no family history of the disorder. These individuals typically have only one malformation.
Cerebral cavernous malformations affect about 16 to 50 per 10,000 people worldwide.
Mutations in at least three genes, KRIT1 (also known as CCM1), CCM2, and PDCD10 (also known as CCM3), cause familial cerebral cavernous malformations.
The precise functions of these genes are not fully understood. Studies show that the proteins produced from these genes are found in the junctions connecting neighboring blood vessel cells. The proteins interact with each other as part of a complex that strengthens the interactions between cells and limits leakage from the blood vessels. Mutations in any of the three genes impair the function of the protein complex, resulting in weakened cell-to-cell junctions and increased leakage from vessels as seen in cerebral cavernous malformations.
Mutations in these three genes account for 85 to 95 percent of all cases of familial cerebral cavernous malformations. The remaining 5 to 15 percent of cases may be due to mutations in unidentified genes or to other unknown causes. Mutations in the KRIT1, CCM2, and PDCD10 genes are not involved in sporadic cerebral cavernous malformations. The cause of this form of the condition is unknown.
This condition has an autosomal dominant pattern of inheritance, which means one copy of the altered gene in each cell is sufficient to cause the disorder. In the familial form, an affected person inherits the mutation from one affected parent.
Most people with cerebral cavernous malformations have the sporadic form of the disorder. These cases occur in people with no history of the disorder in their family.
5. Other Names for This Condition
central nervous system cavernous hemangioma
cerebral cavernous hemangioma
familial cavernous hemangioma
familial cavernous malformation
familial cerebral cavernous angioma
familial cerebral cavernous malformation
intracerebral cavernous hemangioma
- Akers A, Al-Shahi Salman R, A Awad I, Dahlem K, Flemming K, Hart B, Kim H,Jusue-Torres I, Kondziolka D, Lee C, Morrison L, Rigamonti D, Rebeiz T,Tournier-Lasserve E, Waggoner D, Whitehead K. Synopsis of Guidelines for theClinical Management of Cerebral Cavernous Malformations: ConsensusRecommendations Based on Systematic Literature Review by the Angioma AllianceScientific Advisory Board Clinical Experts Panel. Neurosurgery. 2017 May1;80(5):665-680. doi: 10.1093/neuros/nyx091. Review.
- Bergametti F, Denier C, Labauge P, Arnoult M, Boetto S, Clanet M, Coubes P,Echenne B, Ibrahim R, Irthum B, Jacquet G, Lonjon M, Moreau JJ, Neau JP, ParkerF, Tremoulet M, Tournier-Lasserve E; Société Française de Neurochirurgie.Mutations within the programmed cell death 10 gene cause cerebral cavernousmalformations. Am J Hum Genet. 2005 Jan;76(1):42-51.
- Dashti SR, Hoffer A, Hu YC, Selman WR. Molecular genetics of familial cerebralcavernous malformations. Neurosurg Focus. 2006 Jul 15;21(1):e2. Review.
- Denier C, Goutagny S, Labauge P, Krivosic V, Arnoult M, Cousin A, Benabid AL, Comoy J, Frerebeau P, Gilbert B, Houtteville JP, Jan M, Lapierre F, Loiseau H,Menei P, Mercier P, Moreau JJ, Nivelon-Chevallier A, Parker F, Redondo AM,Scarabin JM, Tremoulet M, Zerah M, Maciazek J, Tournier-Lasserve E; SociétéFrançaise de Neurochirurgie. Mutations within the MGC4607 gene cause cerebralcavernous malformations. Am J Hum Genet. 2004 Feb;74(2):326-37.
- Gault J, Sarin H, Awadallah NA, Shenkar R, Awad IA. Pathobiology of humancerebrovascular malformations: basic mechanisms and clinical relevance.Neurosurgery. 2004 Jul;55(1):1-16; discussion 16-7. Review.
- Labauge P, Krivosic V, Denier C, Tournier-Lasserve E, Gaudric A. Frequency of retinal cavernomas in 60 patients with familial cerebral cavernomas: a clinicaland genetic study. Arch Ophthalmol. 2006 Jun;124(6):885-6.
- Marchuk DA, Srinivasan S, Squire TL, Zawistowski JS. Vascular morphogenesis:tales of two syndromes. Hum Mol Genet. 2003 Apr 1;12 Spec No 1:R97-112. Review.
- Plummer NW, Zawistowski JS, Marchuk DA. Genetics of cerebral cavernousmalformations. Curr Neurol Neurosci Rep. 2005 Sep;5(5):391-6. Review.
- Stockton RA, Shenkar R, Awad IA, Ginsberg MH. Cerebral cavernous malformationsproteins inhibit Rho kinase to stabilize vascular integrity. J Exp Med. 2010 Apr 12;207(4):881-96. doi: 10.1084/jem.20091258.
- Sure U, Freman S, Bozinov O, Benes L, Siegel AM, Bertalanffy H. Biologicalactivity of adult cavernous malformations: a study of 56 patients. J Neurosurg.2005 Feb;102(2):342-7.
- Verlaan DJ, Davenport WJ, Stefan H, Sure U, Siegel AM, Rouleau GA. Cerebralcavernous malformations: mutations in Krit1. Neurology. 2002 Mar 26;58(6):853-7. Review.
- Voss K, Stahl S, Schleider E, Ullrich S, Nickel J, Mueller TD, Felbor U. CCM3 interacts with CCM2 indicating common pathogenesis for cerebral cavernousmalformations. Neurogenetics. 2007 Nov;8(4):249-56.
- Zawistowski JS, Stalheim L, Uhlik MT, Abell AN, Ancrile BB, Johnson GL,Marchuk DA. CCM1 and CCM2 protein interactions in cell signaling: implicationsfor cerebral cavernous malformations pathogenesis. Hum Mol Genet. 2005 Sep1;14(17):2521-31.